Evidence map›Paper›PMID 41291137›Full record

ReviewVirchows Archiv : an international journal of pathology2026

The shifting paradigm of programmed cell death ligand 1 (PD-L1) in anaplastic thyroid carcinoma: from pathology to clinical practice.

Vincenzo Fiorentino, Mariagiovanna Ballato, Ludovica Pepe, Valeria Zuccalà, Cristina Pizzimenti, Vincenzo Cianci, Cristina Mondello, Salvatore Cannavò, Alfredo Campennì, Pietro Tralongo and 5 more

Abstract readReview
PubMed Publisher
In one paragraph

Review in Virchows Archiv : an international journal of pathology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Review
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors.

Vincenzo Fiorentino *Anatomic Pathology Unit, Department of Human Pathology in Adult and Developmental Age "Gaetano Barresi", University of Messina, 98125, Messina, Italy.
Mariagiovanna Ballato *PhD Program in Translational Molecular Medicine and Surgery - Department of Biomedical, Dental, Morphological and Functional Imaging Sciences, University of Messina, 98125, Messina, Italy.
Ludovica PepeAnatomic Pathology Unit, Department of Human Pathology in Adult and Developmental Age "Gaetano Barresi", University of Messina, 98125, Messina, Italy.
Valeria ZuccalàAnatomic Pathology Unit, Department of Human Pathology in Adult and Developmental Age "Gaetano Barresi", University of Messina, 98125, Messina, Italy.
Cristina PizzimentiAnatomic Pathology Unit, Papardo Hospital, 98158, Messina, Italy.
Vincenzo CianciSection of Legal Medicine, Department of Biomedical, Dental, Morphological and Functional Imaging Sciences, University of Messina, 98125, Messina, Italy.
Cristina MondelloSection of Legal Medicine, Department of Biomedical, Dental, Morphological and Functional Imaging Sciences, University of Messina, 98125, Messina, Italy.
Salvatore CannavòDivision of Endocrinology - Department of Human Pathology in Adult and Developmental Age "Gaetano Barresi", University of Messina, 98125, Messina, Italy.
Alfredo CampennìDivision of Nuclear Medicine - Department of Biomedical, Dental, Morphological and Functional Imaging Sciences, University of Messina, 98125, Messina, Italy.
Pietro TralongoPhD Program in Translational Molecular Medicine and Surgery - Department of Biomedical, Dental, Morphological and Functional Imaging Sciences, University of Messina, 98125, Messina, Italy.
Giuseppe GiuffrèAnatomic Pathology Unit, Department of Human Pathology in Adult and Developmental Age "Gaetano Barresi", University of Messina, 98125, Messina, Italy.
Gabriele RicciardiPhD Program in Translational Molecular Medicine and Surgery - Department of Biomedical, Dental, Morphological and Functional Imaging Sciences, University of Messina, 98125, Messina, Italy. gabriele.ricciardi@studenti.unime.it.ORCID http://orcid.org/0009-0002-1349-0910
Maurizio MartiniAnatomic Pathology Unit, Department of Human Pathology in Adult and Developmental Age "Gaetano Barresi", University of Messina, 98125, Messina, Italy.
Guido FaddaAnatomic Pathology Unit, Department of Human Pathology in Adult and Developmental Age "Gaetano Barresi", University of Messina, 98125, Messina, Italy.
Esther Diana RossiPoliclinico Universitario "Agostino Gemelli"- IRCCS, Università Cattolica del Sacro Cuore, Largo Francesco Vito, 1, 00168, Rome, Italy.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Anaplastic thyroid carcinoma (ATC) represents one of the most aggressive human malignancies, characterized by rapid progression, early metastasis, and dismal prognosis. The emergence of immune checkpoint blockade targeting the PD-1/PD-L1 axis has revolutionized the therapeutic landscape for several cancers, including ATC, where traditional treatments have shown limited efficacy. This review provide a comprehensive overview of the biological, pathological, and clinical significance of PD-L1 in ATC, highlighting its diagnostic, prognostic, and therapeutic implications. A review of the literature was performed, encompassing molecular studies, immunohistochemical analyses, and clinical trials evaluating PD-L1 expression, its molecular correlates, and its predictive value for immunotherapy response in ATC. PD-L1 is expressed in a substantial proportion of ATCs, with positivity rates ranging from 20% to over 80% depending on the antibody clone, scoring method, and positivity threshold. Its expression correlates with oncogenic drivers such as BRAF

Indexed as

B7-H1 AntigenBiomarkers, TumorThyroid Carcinoma, AnaplasticThyroid NeoplasmsHumansImmune Checkpoint InhibitorsImmunotherapyPrognosisTumor MicroenvironmentB7-H1 AntigenBiomarkers, TumorCD274 protein, humanImmune Checkpoint InhibitorsAnaplastic thyroid carcinomaImmunotherapyPredictive biomarkersProgrammed cell death ligand 1Tumor microenvironment

Identifiers

PMID41291137

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.